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Abstract
Background: Bone metastases are common in many types of cancer. As screening methods
different imaging modalities are available. A new approach for the screening of osseous metastases
represents the measurement of bone metabolic markers. Therefore aim of this study was to
evaluate the usefulness of the determination of bone metabolic markers aminoterminal propeptide
of type I procollagen (PINP, osteoblastic activity) and the carboxyterminal pyridinoline cross-linked
telopeptide of type I collagen (ICTP, osteoclastic activity) for the detection of bone metastases
associated with other malignancies.
Methods: 88 patients aged 21 – 82 years with malignant tumors were prospectively studied. The
serum concentrations of PINP and ICTP were measured and compared to the results of bone
scintigraphy, radiological bone series, CT, MRI and clinical follow-up.
Results: Osseous metastases were found in 21 patients. 19 of them were correctly identified by
bone scintigraphy (sensitivity: 90%). For bone metabolic markers results were as follows: ICTP
sensitivity: 71%, specificity: 42%; PINP sensitivity: 24%, specificity: 96%.
Conclusions: As markers of bone metabolism PINP and ICTP showed low sensitivity and/or
specificity for the detection of osseous metastases. The presented markers did not seem to be
sufficient enough to identify patients with bone metastases or to replace established screening
methods.
Background
Bone metastases are common in advanced cancers of the
lung, breast, kidney, prostate and others. In autopsy stud-
ies the prevalence ranges from 47–85% [1]. In patients
with osseous metastases early detection is needed, since
without effective treatment these bone metastases can
cause severe complications leading to considerable mor-
bidity and reduced quality of life.
The screening for bone metastases is usually based on
bone scintigraphy, confirmed by supplemental radio-
graphic bone surveys, computer tomography, or magnetic
resonance imaging. Bone scans are simple to perform and
examine the whole skeleton, but although the sensitivity
of this method is high its specificity is poor. For this rea-
son, in many cases a positive scan requires confirmation
by other imaging modalities, which leads to higher costs
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and time-consuming investigations. Therefore, an alterna-
tive cost-effective screening method with a similar sensi-
tivity and a higher specificity would be very welcome.
For the formation of osseous metastases the extracellular
matrix consisting of collagens combined with noncolla-
genous glycoproteins and proteoglycans, including the
basement membrane and the interstitial stroma play an
important role. Normally, the extracellular matrix serves
as a barrier for the attachment and invasion of malignant
cells, but the proteolytic activity of tumor cells leads to the
destruction of its collagenic components, thus facilitating
the local invasion of malignant cells and finally the devel-
opment of bone metastases [2]. The major collagen in
bone is type I collagen, which is synthesized by osteob-
lasts and accounts for about 90% of the organic matrix
[3].
Recently, bone metabolic markers have been reported to
be useful in diagnosing bone metastases [4,5]. Newly
developed methods are able to quantitatively determine
concentrations of collagen metabolites. The synthesis of
type I collagen can be analyzed by measuring the serum
concentration of the aminoterminal propeptide of type I
procollagen (PINP) using a specific radioimmunoassay.
In addition, bone resorption can also be analyzed by a
radioimmunoassay, which measures the serum concen-
tration of the carboxyterminal pyridinoline cross-linked
telopeptide of type I collagen (ICTP).
Both parameters have been identified as potential candi-
dates for the early detection of bone metastases. There-
fore, the purpose of this study was to evaluate the
usefulness of PINP and ICTP in patients with newly diag-
nosed cancer for the screening of osseous metastases com-
pared to current standard protocols.
Methods
Patients
For this study 88 consecutive patients (35 female; 53
male) with malignant tumors (20 lung cancer, 20 breast
cancer, 19 head/neck cancer, 5 prostate cancer, 4 thyroid
cancer, 3 sarcoma, 2 esophagus cancer, 2 pancreatic can-
cer, 2 urothel cancer, 1 gastric cancer, 2 plasmocytoma, 2
histiocytosis X, 1 melanoma, 1 rectal cancer, 1 hyperneph-
roma, 2 carcinoma of unknown primary, 1 breast cancer
and hypernephroma) between the ages of 21 and 82 were
included. None of these patients were under a tumor spe-
cific therapy or presented primary bone disease such as
osteoporosis or Paget's disease, which could interfere with
the results of this study. All patients gave written consent
to participate in this prospective study, which was
approved by the local ethics committee.
Marker assays
Blood samples for measuring PINP and ICTP were col-
lected on the same day as bone scintigraphy. Due to
higher PINP values at night, all samples were taken early
in the morning and stored at -20°C until assayed. Appar-
ent hemolytic serum was excluded.
Serum concentrations of ICTP and PINP were measured
by using commercially available RIA kits (both: Orion
Diagnostica, Espoo, Finland). According to the kit
description, the normal range of ICTP was 1.6–5.3 µg/l for
females and 1.4–5.2 µg/l for males. For PINP the normal
range was 19–102 µg/l for females and 21–78 µg/l for
males.
Bone scanning
Two double-head gamma cameras (ECAM duet and Bod-
yscan; Siemens, Erlangen, Germany) and a triple-head
gamma camera (Multispect III, Siemens, Erlangen, Ger-
many) were used for planar and tomographic (SPECT)
bone scans, respectively. Low-energy, high-resolution col-
limators (1024 × 256 matrix) were used and data acquisi-
tion was started 2–4 hrs after intravenous injection of
550–700MBq Tc99m-DPD (3,3-Diphosphono-1,2-pro-
pandicarbonacid). SPECT acquisitions were performed
from suspected regions (128 × 128 matrix; 64 steps;
150000–200000 counts/step; Butterworth filter; cut-off
level 0.4). The total acquisition time ranged from 100 to
130 min for planar and SPECT scans. The bone-scanning
procedure was performed in accordance with procedural
guidelines published by the Society of Nuclear Medicine
[6].
Interpretation of bone scintigraphy
Two experienced nuclear medicine physicians interpreted
planar bone and SPECT images. Initially, neither of the
readers knew of the findings of the other or the results of
other imaging modalities. Increased tracer-uptake located
at joints or on the edge of vertebral bodies adjacent to disk
spaces was interpreted as arthritis or osteophytes, respec-
tively. Lesions were classified as fractures when they
showed a typical linear and curved pattern e.g. adjacent
lesions in the ribs. Multiple lesions of varying size, shape
and intensity, elongated rib lesions or photopaenic areas
(cold spots) were classified as osseous metastases or sus-
picious lesions, where further analysis or imaging meth-
ods were necessary. In general, interpretation was
performed following the criteria described by Krasnow et
al. [7]. Finally, any discrepant interpretations between the
two readers were resolved by consensus. Patients were
classified as having osseous metastases when other imag-
ing modalities (radiographic, MRI, CT) or histological
findings confirmed the diagnosis. Patients were classified
as not having bone metastatic disease when no imaging
technique or histological finding indicated osseousBMC Nuclear Medicine 2004, 4:3 http://www.biomedcentral.com/1471-2385/4/3
Page 3 of 9
(page number not for citation purposes)
involvement. To reduce the possibility that bone metas-
tases were not yet visible by the cited imaging methods, a
clinical follow-up period of between 9–14 months was
used as the gold standard in all patients. Follow-up con-
sisted of a clinical examination, control of tumor markers,
imaging techniques (e.g. computed tomography, MRI or
plain radiographic), etc. Overall, follow-up was done in
compliance with the guidelines for tumor patients pub-
lished by the cancer society.
Data analysis
Sensitivity and specificity were calculated. Values are
expressed as mean ± standard deviation. Statistical analy-
sis was performed using SPSS-Software version 10.0
(SPSS, Inc.). The Mann-Whitney U test was applied to
compare concentrations of PINP and ICTP, respectively. A
value of p < 0.05 was considered to be statistically signifi-
cant. Furthermore, we performed a receiver operating
characteristic (ROC) analysis to assess the impact of bone
metabolic markers in detecting bone metastases.
Results
Osseous metastases were found in 21 patients with the
following tumors: 8 patients with breast cancer, 3 patients
with head/neck cancer and local osseous tumor invasion,
3 prostatic cancer, 2 plasmocytoma, 1 each lung cancer,
histiocytosis X, thyroid cancer and sarcoma and 1 patient
had breast cancer and hypernephroma.
Bone scintigraphy
Using planar and tomographic bone scintigraphy, 19
patients were correctly diagnosed as patients with osseous
metastases by both investigators independently and con-
firmed by other imaging modalities or follow-up (sensi-
tivity: 90%). Two patients were false negative, 1 patient
with histiocytosis X (diffuse infiltration of the spine and
pelvis, identified by computed tomography) and 1 had
breast cancer and hypernephroma (multiple osteolytic
lesions with diameters up to 1.5 cm in the pelvic bone,
which was correctly diagnosed by computed tomogra-
phy). In 43 patients there was no evidence for osseous
metastases by bone scintigraphy or other imaging modal-
ities. In 24 patients, changes in bone scintigraphy were
described not typical for osseous metastases, but addi-
tional imaging methods were recommended for verifica-
tion. Most of these lesions were located in the ribs
(singular focus) and the spine, typically for fractures, trau-
matic injuries or osteoporotic changes (compression frac-
ture). Additional verification was recommended
especially in those patients where no history of traumatic
injuries, degenerative processes or osteoporosis was
known. Verification was done in most cases by plain radi-
ography, computed tomography or within the staging by
FDG-PET.
ICTP
Serum ICTP was elevated above the upper reference limit
(>5.2 µg/ in males and >5.3 µg/l in females) in 56 patients
(31 male, 25 female). In females the mean value was 7.64
± 4.25 µg/l. In the group with metastases (n = 10) the
mean value was 10.71 ± 5.90 µg/l compared to 6.41 ±
2.66 µg/l in the other group (n = 25) without metastases
(p = 0.11). In males the mean value was 8.74 ± 9.49. The
patients with metastases (n = 11) showed a value of 9.23
± 7.62 compared to 8.61 ± 9.99 in patients (n = 42)
without bone metastases (p = 0.24). Figures 1 and 2
present the values of all patients, separated by male and
female, showing the different range of normal values. In
females sensitivity was 70% and specificity 32% and in
males sensitivity was 73% and specificity 48%. For both
groups combined sensitivity was 71% and specificity
42%.
PINP
Serum PINP was elevated above the upper reference limit
(>78 µg/ in males and >102 µg/l in females) in 8 patients
(5 male, 3 female). In females the mean value was 57.42
± 38.50 µg/l. In the group of patients with metastases (n =
10) the mean value was 73.29 ± 62.38 µg/l compared to
51.07 ± 22.23 µg/l in the group (n = 25) without metas-
tases (p = 0.95). In males the mean value was 45.59 ±
43.20. The patients with metastases showed a value of
60.70 ± 83.86 compared to 41.63 ± 23.99 in patients
without bone metastases (p = 0.70). Figures 3 and 4 show
the values of all patients. Sensitivity in females was 30 %,
specificity 100 %, in males sensitivity was 18 %, specificity
93 %. Combined sensitivity was 24 % and specificity 96
%. As examples, figures 6 and 7 show patients with non-
small-cell-lung cancer as the primary tumor.
Values of ICTP in males (Reference interval: 1.4–5.2 µg/) Figure 1
Values of ICTP in males (Reference interval: 1.4–5.2 µg/). 
Red columns indicate patients with osseous metastases.BMC Nuclear Medicine 2004, 4:3 http://www.biomedcentral.com/1471-2385/4/3
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ROC-analysis
Neither parameter achieved statistical significance by
ROC analysis. According to the ROC analysis, the optimal
cut-off level of ICTP that maximizes sensitivity and specif-
icity was 7.5 µg/l in females (60% sensitivity and 88%
specificity) and 5.9 µg/l in males (73% sensitivity and
57% specificity), for PINP 85.5 µg/l in females (40% sen-
sitivity and 96% specificity) and 25.8 µg/l in males (46%
sensitivity and 74% specificity).
Figure 5 shows ROC curves and summarizes the results.
The types of tumors in our study were very heterogeneous,
which reflects the normal day-to-day situation seen in a
department of nuclear medicine. To obtain additional
information concerning special tumor types, we per-
formed a separate examination of two different tumor
types with a higher number of patients: breast cancer and
head/neck cancer.
Breast cancer
The group with breast cancer consisted of 20 patients.
Subsequently, bone metastases could be verified in eight
of these patients. Six cases could be identified clearly by
bone scan, in one patient additional plain radiographic
analysis was recommended to confirm the diagnosis and
one patient was false positive (focal area of increased
tracer uptake in the shaft of the femur, identified as local
necrosis of the bone by plain radiography and confirmed
by follow-up). For bone markers the following results
were observed:
ICTP: sensitivity: 63%, specificity: 25%. PINP: sensitivity:
25%, specificity: 100%. Figure 8 shows an example of a
patient with osseous metastatic disease and normal values
for ICTP and PINP.
Head and neck cancer
19 patients with head/neck cancer were examined (4
female, 15 male). In these patients determination of
whether local osseous structures are involved is essential
for the preoperative planning of further treatment. In
three patients osseous structures were affected by the
Values of ICTP in females (Reference interval: 1.6–5.3 µg/) Figure 2
Values of ICTP in females (Reference interval: 1.6–5.3 µg/). 
Red columns indicate patients with osseous metastases.
Values of PINP in males (Reference interval: 21–78 µg/) Figure 3
Values of PINP in males (Reference interval: 21–78 µg/). Red 
columns indicate patients with osseous metastases.
Values of ICTP in females (Reference interval: 19–102 µg/) Figure 4
Values of ICTP in females (Reference interval: 19–102 µg/). 
Red columns indicate patients with osseous metastases.BMC Nuclear Medicine 2004, 4:3 http://www.biomedcentral.com/1471-2385/4/3
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tumor and all of these were correctly diagnosed by bone
scintigraphy. ICTP and PINP were right positive in two
separate patients. Sensitivity for PINP and ICTP was 33%,
specificity for ICTP was 56% and for PINP 94%.
Discussion
Metastatic bone disease is a serious clinical problem.
Complications associated with osseous metastases are
pain, fractures, spinal cord compression, paralysis, etc.,
which lead to a significant reduction in the quality of life
of tumor patients. Several diagnostic tools are available to
detect bone metastases, including plain radiography,
computer tomography, magnetic resonance imaging and
bone scintigraphy. Of these, radionuclide bone scanning
using Tc-99m labeled diphosphonates is the most widely
used and accepted method for the detection of bone
metastases. Bone scintigraphy can detect osseous metas-
tases several months before changes in plain radiographs
can be seen, thus making bone scintigraphy an excellent
diagnostic tool. However, this method is expensive, is not
always available in every hospital and has the disadvan-
tage of showing a positive reaction even to bone
inflammation, degenerative changes and fractures or flare
reaction, which leads to a reduced specificity. This is the
reason why many authors have described outcomes
regarding diagnosis of bone metastases and observation
of the clinical course using markers of bone turnover.
In recent years, there have been important advances in the
field of biochemical markers of bone turnover and new
left side ROC curves for ICTP and PINP in males Figure 5
left side ROC curves for ICTP and PINP in males Marker AUC ± SE (95%CI) ICTP 0.62 ± 0.1 (0.47–0.75) PINP 0.54 ± 0.1 
(0.40–0.68) AUC: area under curve; SE: standard error; 95%CI: 95% confidence interval  right side ROC curves for ICTP and 
PINP in females Marker AUC ± SE (95%CI) ICTP 0.67 ± 0.1 (0.49–0.82) PINP 0.51 ± 0.1 (0.33–0.68) AUC:area under curve; 
SE: standard error; 95%CI: 95% confidence intervalBMC Nuclear Medicine 2004, 4:3 http://www.biomedcentral.com/1471-2385/4/3
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methods have emerged [8]. Measurement of the metabo-
lites of type I collagen, the predominant collagen in bone,
has been reported to be useful for monitoring bone turn-
over in many different disorders, including diseases with
bone metastases [9].
Yoshida et al. reported on the serum concentration of type
I collagen metabolites as a quantitative marker of bone
metastases in patients with prostate cancer [10]. They con-
cluded that, especially in patients with high grade carci-
noma cells, the determination of bone metabolic markers
should be more useful in evaluating metastatic spread to
bone than prostate specific antigen. In our collective,
patients with prostate cancer (n = 5) showed the highest
correlation between the presence of osseous metastases
and elevated markers for PINP and ICTP. Only in one case
we found a false positive ICTP. However, due to the small
size of our patient groups it prevents any real conclusive
statements from being made.
For other tumor types we did not observe a similar high
correlation. Horiguchi et al. reported on the usefulness of
ICTP as a marker for bone metastases in patients with lung
cancer [11]. He suggested that measurement of ICTP is an
excellent serological diagnostic method for identifying
bone metastases in patients with lung cancer and can also
help predict when it might be useful to undertake other
examinations like bone scintigraphy. In our study how-
ever, we saw a high rate (11 out of 19) of false positive
results of increased ICTP levels in this group of patients.
One reason for this might be the presence of non-detecta-
ble micro-metastases at the time of ICTP measurement. To
avoid the possibility of false results, all patients had a fol-
low-up examination between 9 and 14 months, during
Bone scan of a 59-year-old female with non-small-cell lung cancer and multiple osseous metastases Figure 6
Bone scan of a 59-year-old female with non-small-cell lung cancer and multiple osseous metastases. Both parameters are 
increased ICTP: 13 µg/L (1.6–5.3) PINP: 113.8 µg/L (19–102)BMC Nuclear Medicine 2004, 4:3 http://www.biomedcentral.com/1471-2385/4/3
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which micro-metastases would have become apparent.
None of the 11 patients developed osseous metastases
during this time period so that the likelihood of the pres-
ence of such metastases was very low.
Another major group of patients in our study were females
with breast cancer. The literature on these tumors and the
value of bone metabolic markers for detection of osseous
metastases is very controversial. Blomqvist et al. reported
a positive and significant correlation between ICTP and
PICP and the number of bone metastases, plus Wada et al.
suggested that ICPT might be a useful marker for screen-
ing and monitoring bone metastases in breast cancer
[12,13]. In contrast Ulrich et al. showed in a study with
106 patients that the sensitivity for diagnosing bone
metastases was 65% [14]. These results are more similar to
our study. However, Ulrich reported a high specificity of
91%, whereas we observed only 25% specificity for ICTP.
The types of tumors in our study were very heterogeneous,
which seems to reflect the circumstances seen on a daily
basis. Due to the fact that tumors can metastasize to bone
in different ways (osteoblastic and/or osteolytic) we
established parameters for both possibilities. For PINP,
the marker for osteoblastic activity, the specificity was
high but with a poor sensitivity. For ICTP, the marker for
osteolytic activity, both characteristics of sensitivity and
specificity were low, such that a general recommendation
for the use of this marker as a screening parameter cannot
be made.
Potential indications for bone metabolic markers might
be the therapy control in patients with bone metastases, in
Bone scan of a 47-year-old male with non small cell lung cancer Figure 7
Bone scan of a 47-year-old male with non small cell lung cancer. Bone scintigraphy and follow-up showed no evidence of 
osseous metastatic disease. ICTP: 7.3 µg/L (1.4–5.2) and PINP: 102 µg/L (21–78) are above the upper reference limit.BMC Nuclear Medicine 2004, 4:3 http://www.biomedcentral.com/1471-2385/4/3
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which increased parameters had been proven before ther-
apy. Particularly in these patients, the so-called "bone
flare reaction", the repair of destroyed bone structures by
tumor cells, complicates the assessment of bone scintigra-
phy. Increased activity in known osseous metastases after
or during therapy can be caused by either repair or further
tumor growth. Blomqvist and colleagues and Koizumi et
al. reported on patients with breast cancer and osseous
metastases, where only patients with progressive disease
showed an increase in ICTP values during therapy com-
pared to other patients with response to therapy [9,15].
Another indication might be in benign bone disorders
like rheumatoid arthritis or Paget's disease. Aman et al.
reported a correlation between ICTP values and the dis-
ease progression of patients with rheumatoid arthritis
[16].
Conclusions
In summary, when a new method is recommended for the
diagnostic work up, it is necessary to demonstrate that this
new modality is as sensitive and specific as existing rou-
tine imaging procedures. The determination of bone met-
abolic parameters like ICTP or PINP is less expensive than
bone scanning, but this prospective study has shown that
the results from bone metabolic markers are not yet suffi-
cient enough to demonstrate a bone involvement in dif-
ferent type of malignancies with high sensitivity and
specificity.
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